Substances Authority for information on how to prevent and detect abuse or diversion of this product. Interactions with other CNS Depressants. Medscape – Detoxification, pain-specific dosing for Methadose, Dolophine opioids; Substantial interpatient variability, see prescribing information for guidance. Find patient medical information for Dolophine Oral on WebMD including its uses , side effects and safety, interactions, pictures, warnings and user ratings.
|Published (Last):||19 January 2007|
|PDF File Size:||10.83 Mb|
|ePub File Size:||12.75 Mb|
|Price:||Free* [*Free Regsitration Required]|
Start these patients on lower doses and titrate slowly while carefully monitoring for signs of respiratory and CNS depression.
Infants born to narcotic-addicted women treated with methadone during pregnancy have been found to have decreased fetal growth with reduced birth weight, length, or head circumference. Monitor patients for symptoms of opioid-induced endocrinopathy.
Whenever possible, pain management should be colophine with health care providers before any surgery or dental work takes place.
Methadone should be reserved for patients in whom alternative treatment options e. Local tissue reactions may occur with SC use. It is important to note respiratory depressant effects occur later and persist longer than peak analgesic effects.
For the treatment of moderate to severe pain not responsive to non-narcotic analgesics. Measure dosage using a calibrated measuring device. Initial doses may need to be reduced, and doses should be carefully titrated taking into account analgesic effects, adverse reactions, and concomitant drugs that may depress respiration.
The growth deficit does not appear to persist into later childhood. Serious or fatal respiratory depression can occur at any time during the use of methadone; however, the risk informstion greatest during the first 24 to 72 hours after therapy initiation or dose titration.
Methadone Dolophine, Methadose – Treatment – Hepatitis C Online
In addition, chronic inrormation use may lead to symptoms of hypogonadism, resulting from changes in the hypothalamic-pituitary-gonadal axis. Additionally, avoid coadministration with other CNS depressants when possible as this significantly increases the risk for respiratory depression, low blood pressure, and death.
Disperse tablets 3—4 ounces 90— ml of water, orange juice, citrus Tang, citrus prescibing of Kool-Aid, or other acidic fruit beverages prior to patient administration. Angina, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, hypotension, hypovolemia, long QT syndrome, malnutrition, myocardial infarction, orthostatic hypotension, QT prolongation, thyroid disease.
In opioid-tolerant patients, convert the current total daily dose of all opioids to an oral morphine equivalent dose, then multiply the morphine equivalent dose by the corresponding percentages in the dose conversion table provided in the FDA-approved labeling.
Chronic opioid use may influence the hypothalamic-pituitary-gonadal axis, leading to hormonal changes that may manifest as hypogonadism gonadal suppression and pose a reproductive risk. Other opioids may be tried; some cases reported use of a different opioid with no recurrence predcribing adrenocortical insufficiency.
Drug accumulation or prolonged duration of action can occur in patients with hepatic disease. Use extreme caution to avoid overdosage; it is safer to underestimate a patient’s daily oral methadone requirement.
False positive urine drug screens for methadone have been reported for several drugs including diphenhydramine, doxylamine, clomipramine, chlorpromazine, thioridazine, quetiapine, and verapamil.
Reserve concomitant use of these drugs for patients in whom alternative treatment options are inadequate. During chronic administration of methadone, monitor patients for persistent constipation and maintain an effective bowel regimen. No increased risk of miscarriage in the second trimester or premature delivery in the third trimester was noted by a retrospective review of data from opioid-dependent women. Methadone clearance may be increased during pregnancy.
When administered as an analgesic, methadone may be dispensed by any licensed pharmacy. When the patient no longer requires methadone, taper the dose gradually every 2 to 4 days to prevent withdrawal in the physically-dependent patient.
Methadone is associated with an increased risk for QT prolongation and torsade de pointes TdP. Individuals receiving palliative care or those in hospice settings are excluded from the Beers Criteria; the balance of benefits and harms of medication management for these patients may differ from those of the general population of older adults. Consider these risks in pregnant women treated with methadone for maintenance treatment of opioid addiction.
Although opiate agonists are contraindicated for use in patients with diarrhea secondary to poisoning or infectious diarrhea, antimotility agents have been used successfully in these patients. When used for analgesia, methadone should be reserved for use in patients for whom alternative treatment options e. Methadone is an opioid agonist and therefore has abuse potential and risk of fatal overdose from respiratory failure.
Due to the effects of opiate agonists on the gastrointestinal tract, methadone is contraindicated in patients with known or suspected rpescribing ileus. If possible, opiate agonists should not be given until the toxic substance has been eliminated. Adjust dosage based upon clinical response; no specific quantitative recommendations are available.
BOXED WARNING Angina, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, hypotension, hypovolemia, long QT syndrome, malnutrition, myocardial infarction, orthostatic hypotension, QT prolongation, thyroid disease.
Patients presenting with signs or symptoms of androgen deficiency should undergo laboratory evaluation. If a patient is taking methadone and experiences acute pain such as postoperative pain, analgesia may not be provided by the existing methadone dose; administration of another analgesic may be warranted.
Loss of opioid tolerance should be considered for a patient who has not taken opioids for more than 5 days. Do,ophine treatment of respiratory depression in an individual physically dependent on opioids is necessary, administer the opioid antagonist with extreme care; titrate the antagonist dose by using smaller than usual doses.
Methadone has not been extensively evaluated in patients with renal insufficiency. Use methadone with caution in patients with adrenal insufficiency i.
Various dosing regimens have been inforkation and some practitioners suggest the daily dosage of opioid infusion e. Inject into a large muscle mass.
Any decrease in methadone dosage could precipitate a relapse to illicit drug use, and patients should be informed of the high risk of relapse.
Maintenance should be continued as long as desired by the patient and as long as continued benefit is derived from treatment. There are no adequate and well-controlled studies with methadone in pregnant women. Advise breast-feeding women taking methadone to monitor the infant for increased drowsiness and breathing difficulty.
Methadone has been detected in very low plasma concentrations in some infants whose mothers were taking methadone. Opioid withdrawal symptoms have been associated with an increased risk of relapse to illicit drug use.